SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Cazzola M) srt2:(2010-2014)"

Sökning: WFRF:(Cazzola M) > (2010-2014)

  • Resultat 1-10 av 25
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Fenaux, P, et al. (författare)
  • A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
  • 2011
  • Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 118:14, s. 3765-3776
  • Tidskriftsartikel (refereegranskat)abstract
    • This phase 3, randomized, double-blind study assessed the efficacy and safety of lenalidomide in 205 red blood cell (RBC) transfusion-dependent patients with International Prognostic Scoring System Low-/Intermediate-1-risk del5q31 myelodysplastic syndromes. Patients received lenalidomide 10 mg/day on days 1-21 (n = 69) or 5 mg/day on days 1-28 (n = 69) of 28-day cycles; or placebo (n = 67). Crossover to lenalidomide or higher dose was allowed after 16 weeks. More patients in the lenalidomide 10- and 5-mg groups achieved RBC-transfusion independence (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% and 42.6% vs 5.9%; both P < .001). Median duration of RBC-TI was not reached (median follow-up, 1.55 years), with 60% to 67% of responses ongoing in patients without progression to acute myeloid leukemia (AML). Cytogenetic response rates were 50.0% (10 mg) versus 25.0% (5 mg; P = .066). For the lenalidomide groups combined, 3-year overall survival and AML risk were 56.5% and 25.1%, respectively. RBC-TI for ≥ 8 weeks was associated with 47% and 42% reductions in the relative risks of death and AML progression or death, respectively (P = .021 and .048). The safety profile was consistent with previous reports. Lenalidomide is beneficial and has an acceptable safety profile in transfusion-dependent patients with Low-/Intermediate-1-risk del5q myelodysplastic syndrome. This trial was registered at www.clinicaltrials.gov as #NCT00179621.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Bennaceur, A., et al. (författare)
  • Mechanisms for leveraging models at runtime in self-adaptive software
  • 2014
  • Ingår i: Lecture Notes in Computer Science: Dagstuhl Seminar 11481 on Models@run.time; ; 27 November 2011 through 2 December 2011. - Cham : Springer. - 9783319089140
  • Konferensbidrag (refereegranskat)abstract
    • Modern software systems are often required to adapt their behavior at runtime in order to maintain or enhance their utility in dynamic environments. Models at runtime research aims to provide suitable abstractions, techniques, and tools to manage the complexity of adapting software systems at runtime. In this chapter, we discuss challenges associated with developing mechanisms that leverage models at runtime to support runtime software adaptation. Specifically, we discuss challenges associated with developing effective mechanisms for supervising running systems, reasoning about and planning adaptations, maintaining consistency among multiple runtime models, and maintaining fidelity of runtime models with respect to the running system and its environment. We discuss related problems and state-of-the-art mechanisms, and identify open research challenges.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 25

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy